In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Protalix BioTherapeutics Inc.

www.protalix.com

Latest From Protalix BioTherapeutics Inc.

Bookmark
  • News

Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal

By Scrip Team

LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.

Deals M & A
Bookmark
  • News

More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE

By Francesca Bruce

Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.

Rare Diseases Health Technology Assessment
Bookmark
  • News

Chiesi Committed To Becoming A Major Player In Rare Diseases

By Kevin Grogan

The Italian group has got the green light in Europe for Lamzede, the first disease-modifying therapy for alpha mannosidosis and believes the drug, along with Procysbi and an investigational Fabry disease being developed with Protalix, constitute a strong portfolio in the rare metabolic disease area.

Rare Diseases Metabolic Disorders
Bookmark
  • News

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

By John Davis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Protalix BioTherapeutics Ltd.
  • Metabogal Ltd.
  • Orthodontix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Protalix BioTherapeutics Inc.
  • Senior Management
  • Dror Bashan, Pres. & CEO
    Yossi Maimon, CFO
    Yoseph Shaaltiel, PhD, EVP, R&D
    Ronen Rosenberg, VP, Commercial & Product Planning
    William Taylor, VP, Bus. Dev.
  • Contact Info
  • Protalix BioTherapeutics Inc.
    Phone: (972) 4-902-8100
    2 Snunit St., Science Park
    P.O. Box 455 Karmiel, 21000
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By